最新ニュース Nuvalent (NASDAQ:NUVL) 株価情報

Nuvalent

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

News

Movers

ACLS

AGIO

HALO

IRTC

LBTYB

LEGN

NEOG

NUVL

NVAX

NVDA

SMAR

TWST

VRNT

これらの中型株は直近1週間で最も好調のパフォーマンスを示しました。あなたのポートフォリオには入っていますか？

直近1週間高パフォーマンスを示したのは、中型株

Nuvalent Inc

In a report released on September 13, Richard Law CFA from Goldman Sachs reiterated a Sell rating on Nuvalent (NUVL – Research Report). The company...

Goldman Sachs Remains a Sell on Nuvalent (NUVL)

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Nuvalent (NUVL – Research Report), with a price target of $100.00...

Nuvalent (NUVL) Gets a Buy from Barclays

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Nuvalent (NUVL – Research Report) today and set a price target of $100.00. The...

Nuvalent (NUVL) Receives a Buy from Piper Sandler

Nuvalent jumps 19% on $350M equity offering

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Nuvalent (NUVL – Research Report). The company's shares closed last...

Nuvalent (NUVL) Receives a Buy from TD Cowen

Nuvalent announces pricing of $500M upsized stock offering

Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

New small-cap buy and sell ideas for Oppenheimer's 50/50 list

APLE

CWEN

PATK

RHHBF

RHHBY

RHHVF

VKTX

Press Releases

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024

Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

Earnings

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Offerings

Nuvalent Announces Public Offering of Common Stock

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

ADMA Biologics

Alkermes

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biohaven

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Viking Therapeutics

JP Morgan

Guggenheim

Wedbush

BMO Capital

Stifel

これらの中型株は直近1週間で最も好調のパフォーマンスを示しました。あなたのポートフォリオには入っていますか？
<ol>
<li>Agios Pharmaceuticals Inc(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>)株は、企業が依存性輸血（TD）アルファまたはベータ地中海貧血の患者を対象にした臨床試験で<a href="https://www.benzinga.com//node/39141375">主要エンドポイントを達成</a>したと発表した後、先週29.13％急騰しました。 この発表を受けて、数人のアナリストが予測を<a href="https://www.benzinga.com/quote/agio/analyst-ratings">引き上げました</a>。</li>
<li>Verint Systems Inc。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>）の株価は、同社が先週火曜日に<a class="ticker" href="https://www.benzinga.com//node/39170267" target="_blank" rel="noreferrer noopener">予想を上回るQ1業績を発表し、強いFY25業績予測を示した</a>ことを受けて22.40％上昇しました。</li>
<li>Novavax Inc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>）の株は先週、米国食品医薬品局（FDA）の諮問委員会が新型コロナウイルスのJN.1系統向けの<a href="https://www.benzinga.com/general/biotech/24/06/39204978/novavax-stock-rallies-in-pre-market-as-company-plans-to-deliver-covid-19-vaccine-by-september">更新されたワクチンの推奨を可決した</a>と発表した後、21.54％上昇しました。</li>
<li>Nuvalent, Inc。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>）の株は20.52％上昇しました。</li>
<li>Neogen Corporation（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>）の株は19.25％上昇しました。</li>
<li>Twist Bioscience Corporation（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>）の株価は、Guggenheimが<a class="ticker" href="https://www.benzinga.com/quote/twst/analyst-ratings" target="_blank" rel="noreferrer noopener">株を「Buy」のレーティングでカバーし、53ドルの</a><a href="https://www.benzinga.com//node/39206468" target="_blank" rel="noreferrer noopener">株価ターゲットを発表した</a><a class="ticker" href="https://www.benzinga.com/quote/twst/analyst-ratings" target="_blank" rel="noreferrer noopener">ことで18.40％急騰しました。</a></li>
<li>Smartsheet Inc。（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>）の株価は、同社が予想を上回るQ1業績を発表し、<a href="https://www.benzinga.com//node/39195040" target="_blank" rel="noreferrer noopener">初めての1億5000万ドルの株買い戻しプログラムを発表した</a>ことで18.01％上昇しました。 これを受け、多くのアナリストが<a href="https://www.benzinga.com//node/39206468" target="_blank" rel="noreferrer noopener">株価ターゲットを変更しました</a>。</li>
<li>Halozyme Therapeutics, Inc。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>）の株価は14.03％急伸し、同社が<a href="https://www.benzinga.com//node/39211537" target="_blank" rel="noreferrer noopener">FY24業績見通しを引き上げた</a>ことが要因です。</li>
<li>Legend Biotech Corporation（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>）の<a href="https://www.benzinga.com/quote/legn/analyst-ratings" target="_blank" rel="noreferrer noopener">株価が13.93％上昇しました</a>。</li>
<li>Liberty Global Ltd。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYB#NASDAQ">LBTYB</a>）の株価は12.48％上昇しました。</li>
</ol>

Comments

Nuvalent

ニュース

最新ニュース Nuvalent (NASDAQ:NUVL) 株価情報

月曜日, 6 10, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル